Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award - Priority Announcement: HIV/AIDS Research (SHOPP)

University of Toronto

$72,000.00

Clinical and immune correlates of isolated semen HIV shedding

EF 2010-11

Résumé
The global prevalence of HIV-1 is 0.8% with the number of persons living with HIV continuing to increase as a result of global population growth, continued transmission, and antiretroviral-associated reductions in mortality. With no cure or vaccine likely in the short term, understanding factors that affect HIV transmission is pivotal to the design of new prevention and treatment strategies. The advent of antiretroviral therapy had a dramatic effect on the HIV community through its ability to suppress HIV replication to often-undetectable levels in blood (effective ART). However, it has been estimated that even with effective antiretroviral therapy, transmission still occurs roughly 10% of the time. Previous work by our lab has identified a subgroup of men, who despite effective ART with no clinical STI or urethritis, shed High-level HIV in their semen, leaving them in a potentially infectious state. Various studies have shown that while ART compounds penetrate into the semen, many of them only do so to low levels. We propose to investigate whether an "intensified" drug therapy (standard therapy + two additional drugs of differing mechanistic class), can prevent the occurrence of isolated semen shedding. In addition we plan to investigate whether an unidentified infection localized to the male genital tract is responsible for the inability of therapy to suppress viral replication. Preliminary data has shown evidence of immune activation in semen but not blood in those men shedding. Finally we plan to investigate the phenomenon of disproportionate semen HIV shedding. A situation where a ART drug naïve person has higher HIV levels in semen then blood. We will investigate various immunological correlates to determine potential immune mechanisms for this occurrence.
Programme
Doctoral Research Award - Priority Announcement: HIV/AIDS Research (SHOPP)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
218729
Name
Osborne Brendan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association for HIV Research (Ottawa)
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
Clinical and immune correlates of isolated semen HIV shedding
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$72,000
Cihrequipment2
$0
Programname2
Doctoral Research Award - Priority Announcement: HIV/AIDS Research (SHOPP)
Keyworddelim
Clinical Investigation; Flow Cytometry; Genital Mucosa; Hiv; Immunology; Infectious Disease; Semen; Sexually Transmitted Disease; T Cells; Tissue Culture
Abstract
The global prevalence of HIV-1 is 0.8% with the number of persons living with HIV continuing to increase as a result of global population growth, continued transmission, and antiretroviral-associated reductions in mortality. With no cure or vaccine likely in the short term, understanding factors that affect HIV transmission is pivotal to the design of new prevention and treatment strategies. The advent of antiretroviral therapy had a dramatic effect on the HIV community through its ability to suppress HIV replication to often-undetectable levels in blood (effective ART). However, it has been estimated that even with effective antiretroviral therapy, transmission still occurs roughly 10% of the time. Previous work by our lab has identified a subgroup of men, who despite effective ART with no clinical STI or urethritis, shed High-level HIV in their semen, leaving them in a potentially infectious state. Various studies have shown that while ART compounds penetrate into the semen, many of them only do so to low levels. We propose to investigate whether an "intensified" drug therapy (standard therapy + two additional drugs of differing mechanistic class), can prevent the occurrence of isolated semen shedding. In addition we plan to investigate whether an unidentified infection localized to the male genital tract is responsible for the inability of therapy to suppress viral replication. Preliminary data has shown evidence of immune activation in semen but not blood in those men shedding. Finally we plan to investigate the phenomenon of disproportionate semen HIV shedding. A situation where a ART drug naïve person has higher HIV levels in semen then blood. We will investigate various immunological correlates to determine potential immune mechanisms for this occurrence.
Competitiondate
201010
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Osborne, Brendan
Approvedterm
3 ans 0 mois
Cihrcontribution2
SPIR~ $72,000~ $0~